Abstract 187P
Background
Chemoradiation in Stomach is indicated in patients who do not receive perioperative chemotherapy. While contouring the organs at risk in CRT of stomach spleen is not considered as the organ at risk (OARS). Leukopenia is also seen very commonly during the CRT of stomach. We are trying to correlate the grade of leukopenia to the dose received by spleen during CRT of stomach. The primary aim of this study -To determine the dose achieved by Spleen during the Post Operative Adjuvant Radiotherapy of Carcinoma Stomach. Correlate the dose achieved to the weekly blood counts (Grade 3 Hematological Toxicity).
Methods
Patients attending Kasturba Medical College OPD diagnosed with Carcinoma Stomach and planned for Adjuvant Chemoradiation were considered for the study. We analyzed 42 patients from the Jan 2018 to December 2018. The Dosimetric and Volumetric Parameters were calculated for Spleen. The patients in our study underwent Upfront Gastrectomy (Total/Partial) and received 2 cycles of Adjuvant Chemotherapy (CAPOX). Then referred for adjuvant Chemoradiation.
Results
The Mean dose achieved was 36 Gy. The range of dose received by the spleen ranged from 35Gy- 45 Gy. The doses were high when splenic nodes were irradiated. 18 patients (42%) presented with Grade 3 Hematological toxicity( Leukopenia). 15 patients (35%) could not receive Concurrent Chemotherapy in view of non recovery of Hematological Toxicities.
Conclusions
From our study we found that Spleen is a Dose limiting Structure while planning the Adjuvant Post Operative Radiotherapy in Carcinoma Stomach. The dose received by spleen can be correlated with the grade of Leukopenia in patients receiving adjuvant CRT for Carcinoma Stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr Umesh Velu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract
426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy
Presenter: Nobumichi Takeuchi
Session: Poster display session
Resources:
Abstract